Monday, 6 April 2020

Vocal Cord Paralysis Market Swot Analysis, Major Key Players Revenue, Analysis And Forecasts To 2023

The global vocal cord paralysis market is poised to touch a valuation of USD 2,920.2 million by 2023, as per the latest report by Market Research Future (MRFR). It was valued at USD 2,334.7 million in 2017. Vocal cord paralysis occurs when one or both vocal cords are damaged owing to interruptions of nerve impulses in the larynx or voice box. High prevalence of brain injuries during surgeries is one of the major factors driving the market growth from 2018 to 2023 (forecast period). According to the Center for Disease Control and Prevention (CDC), nearly 2.5 million suffered a traumatic brain injury in the U.S. alone.
Rising incidence of neck, larynx, and head cancers can boost market demand over the forecast period. The number of cancer cases with the larynx at its core had shot up to 13,360 in the U.S. Technological breakthroughs in the medical sector such as laryngoscopy, endoscopy, and laryngeal electromyography can positively affect the vocal cord paralysis market. These procedures have significantly improved the accuracy and diagnosis rate of discerning vocal cord paralysis. But high treatment costs of vocal cord paralysis can impede market growth.
Segmentation:
The vocal cord paralysis market can be segmented by type and treatment.

By type, the market is segmented into unilateral and bilateral. The unilateral segment accounted for 89.3% market share in 2017, while the bilateral segment registered 10.7% share in the same year. Unilateral can accrue revenue at a 3.6% CAGR over the forecast period. This can be attributed to the rise of voice disorders, the increasing healthcare expenditure of developing economies, and favorable medical reimbursement schemes. On the other hand, the bilateral segment can exhibit 3.80% CAGR over the review period.
By treatment, it is segmented into voice therapy and surgery. The voice therapy segment was valued at USD 1,508.7 million in 2017. It is touted to register a 3.4% CAGR during the assessment period. This can be attributed to low risk involved with the treatment as compared to its counterpart. It can reach a market valuation of USD 1,848.7 million by 2023. The surgery segment can exhibit 3.83% CAGR till 2023 owing to the slew of surgical procedures for various voice disorders.
Regional Analysis:
The vocal cord paralysis market covers the latest trends and opportunities across Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas dominated the market with 35.4% share in 2017, followed by Europe and APAC respectively. Its market size can mushroom to USD 1,007.5 million by 2023, growing at 3.4% CAGR over the forecast period. This can be attributed to awareness of the medical condition and sophisticated healthcare infrastructure in place to handle the prevalence of voice paresis.
The Europe vocal cord paralysis market can expect to generate revenue at a 3.37% CAGR over the forecast period. Government support to the healthcare sector coupled with reimbursement policies can boost the regional valuation to USD 958.1 million by 2023.
The APAC region is touted to grow at a robust pace owing to the huge patient pool, dearth of growth opportunities, increased healthcare expenditure, and developing healthcare sector. Increasing prevalence of laryngeal cancer and affordable treatment options can facilitate regional growth over the assessment period. This region can generate close to USD 697.42 million by 2023, exhibiting a 4.11% CAGR till 2023.
The MEA market will hold the least market share by 2023, growing at a 3.90% CAGR over the forecast period.
Competitive Dashboard:
Prominent players operating in the vocal cord paralysis market include Therapy Solutions Inc. (U.S.), Stryker Corporation (U.S.), Olympus Corporation (Japan), FUJIFILM Holdings Corporation (Japan), Smiths Group Plc (U.K.), Teleflex Incorporated (U.S.), LifeCell Corporation (U.S.), Medtronic Plc (U.S.), KARL STORZ GmbH & Co. KG (Germany), and Cytophil, Inc. (U.S.). The market is highly competitive in nature with big and small players fighting for a higher share. Expansions and acquisitions are major strategies employed by these players.
Posted by at No comments:

Worldwide ICP-OES Spectrometer Market 2019 Synpsis With Leading Players, Industry Growth Factor Foresight By 2025

Market Highlights
The global ICP-OES spectrometer market was valued at USD 521.4 million in 2018 at a CAGR of 7.2% during the forecast period of 2019 to 2025.
ICP-OES Spectrometer is an analytical instrument that is used for the detection of chemical elements. It uses the technique of inductively coupled plasma optical emission spectroscopy (ICP-OES) for carrying out its analysis procedure. Certain factors that propel the growth of the ICP-OES spectrometer market include increasing R&D expenditure for the development of better analytical systems and growing technological advancements.
However, the high cost of instruments and requirement of large capital investment for setting up instrument manufacturing plants is hindering the growth of the global ICP-OES spectrometer market in the forecast period.
Currently, the global ICP-OES spectrometer market is dominated by several players. The major players in this market are involved in strategic acquisitions and product launches to expand their product portfolios. For instance, in March 2016, GBC Scientific Equipment launched the OptiMass 9600, which uses the ICP-OES spectrometer technology.
Segmental Analysis
The global ICP-OES spectrometer market has been segmented based on spectrometer type, application, end user, and region.
The market, based on spectrometer type, has been segmented into sequential and simultaneous. The sequential spectrometer market is expected to hold a major share in the market owing to its wider availability in the market. The sequential spectrometer market is anticipated to be the fastest-growing due to its rising adoption rate in the industry.
The market, by application, has been divided into nanotechnology, drug discovery, environmental testing, food & agriculture, and others. The drug discovery segment is expected to hold a major share owing to its large number of applications in the market. The environmental testing segment is expected to be the fastest-growing due to the rising number of research activities for using ICP-OES spectrometer for environmental testing purpose.
The market, by end user, has been classified as pharmaceutical & biotechnology companies, research & academic institutes, and others. The pharmaceutical and biotechnology companies’ segment is anticipated to hold a major share in the market due to the increasing number of applications of ICP-OES spectrometer in the pharmaceutical industry. The research & academic institutes segment is expected to be the fastest-growing market due to the rising number of research activities.
Key Players
Some of the key players in the global ICP-OES spectrometer market are PerkinElmer Inc. (US), Shimadzu Corporation (Japan), GBC Scientific Equipment (Australia), Thermo Fisher Scientific (US), Agilent Technologies, Inc. (US), SPECTRO Analytical Instruments GmbH (Germany), Teledyne Leeman Labs (US), Analytik Jena AG (Germany), Horiba (Japan), Skyray Instrument Inc. (US), Beijing Huake Tiancheng Technology Co., Ltd (China), FPI (China), Hitachi High-Technologies Corporation (Japan), Merck KGaA (Germany), and others.
Regional Analysis
The global ICP-OES spectrometer market, by region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ICP-OES spectrometer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European ICP-OES spectrometer market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The ICP-OES spectrometer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The ICP-OES spectrometer market in the Middle East & Africa has been divided into the Middle East and Africa.
Posted by at No comments:
Labels:

Laboratory Informatics Market Overview By Trends, Industry Top Manufactures, Size, Industry Growth Analysis & Forecast Till 2024

Market Highlights
The global laboratory informatics market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 2422 million in 2018 and is projected to register a CAGR of 7.2% over the forecast period.
The increasing participation of key players is one of the key factors driving the laboratory information system market. In 2018, Sysmex Corporation, Japan-based company, launched a new network solution Caresphere. The solution is designed to provide new value through the intelligent use of information by people involved in testing and healthcare.
Various other factors such as the increase in adoption of cloud-based platforms by CROs, increasing preference towards personalized medicine, untapped emerging markets, rise in regulatory approvals, and rising R&D in the field of medicine are also expected to propel the growth of the market.
However, high maintenance and service costs can hamper market growth over the forecast period.
Segmentation
The global laboratory informatics market is segmented based on product, component, deployment model, end user, and region.
The global market for laboratory informatics, by product, is segmented into Laboratory Information Management Systems (LIMS), Chromatography Data Systems (CDS), Electronic Lab Notebooks (ELN), Electronic Data Capture (EDC) & Clinical Data Management Systems (CDMS), Laboratory Execution Systems (LES), Enterprise Content Management (ECM), and Scientific Data Management Systems (SDMS). The Laboratory Information Management Systems (LIMS) segment is further classified as broad-based LIMS and industry-specific LIMS.
Based on component, the market is segmented into software and services.
Based on the deployment model, the market is segmented into on-premise models, cloud-based models, and remotely hosted models.
Based on end user, the market is segmented into life sciences companies, CROs, environmental testing laboratories, and others. The CROs segment is expected to witness the fastest growth over the forecast period due to increasing adoption by outsourcing companies to reduce healthcare costs.
Key Players
Some of the key players in the global laboratory informatics market are Agilent Technologies, Inc., Abbott Laboratories, Accelerated Technology Laboratories, Cerner Corporation, Dassault Systèmes, IDBS, KineMatik, Lablynx, Inc., Labvantage Solutions, Inc., Autoscribe Limited, Labware, Labworks LLC, McKesson Corporation, Thermo Fisher Scientific Inc., Perkinelmer Inc., Waters, and others.
Regional Analysis
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The laboratory informatics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European laboratory informatics market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The laboratory informatics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The laboratory informatics market in the Middle East & Africa has been segmented into the Middle East and Africa.
Posted by at No comments:
Labels:

CBD Market Worldwide Key Players Forecasts By Revenue, Growth Rate Till 2026

Market Highlights
The Global CBD Market was valued at USD 570 Million in 2018 and is expected to register a CAGR of 125.58% during the forecast period.
The global CBD market was valued at USD 3,088.51 million in 2018, and the market is estimated to grow at USD 2,207,162.54 Million by 2026 and is expected to register a CAGR of 125.58% during the forecast period from 2019 to 2026. In 2018, the Americas accounted for the largest market share of 78.14% with a market value of USD 2,413.34 million, followed by Europe with a market value of USD 358.19 million in 2018.
Based on form, the liquid segment accounted for the largest market share of 51.86% in 2018, with a market value of USD 1,601.62 million and is projected to register a CAGR of 127.24% during the forecast period. On the basis of routes of administration, the tincture segment accounted for the largest market share of 36.65% in 2018, with a market value of USD 1,132.07 million, and is projected to register a CAGR of 126.54% during the forecast period.
Segment Analysis
The global CBD market has been segmented on the basis of form, routes of administration, by product, application, end user, source, and by region.
On the basis of form, the global cannabidiol market is segmented into solid and liquid. The solid form of CBD is segmented into CBD crystals, CBD wax, capsule/softgel, hash, and others. The liquid form of CBD includes CBD oil, tincture, cream, e-liquid, and others. On the basis of product, the global cannabidiol market is segmented into food grade, therapeutic grade, and others. On the basis of application, the global cannabidiol market is segmented into neurogenerative disorder, fibromyalgia, diabetes, energy drinks, protein bars, and others. On the basis of end user, the global cannabidiol market is segmented into healthcare, food & beverage, and others. On the basis of source, the global cannabidiol market is segmented into inorganic and organic.
Market Players
Market Research Future (MRFR) recognizes Aphria Inc., Folium Biosciences, Freedom Leaf, Inc, Green Roads of Florida, LLC, CBD Health Solutions, LLC, ENDOCA, Isodiol International Inc, CV Sciences, Inc, Medical Marijuana, Inc., Canopy Growth Corporation, Elixinol Global Limited as the key players in the global CBD market.
Regional Analysis
The CBD market in the Americas has been segmented into North America and Latin America. The North American market is further divided into the US and Canada. Latin America market is classified into Brazil and the rest of Latin America. The Americas dominate the global CBD market, owing to the increasing consumption of cannabis-based products. The rising demand for cannabis has raised the market potential in the American region. A poll conducted by Gallup Inc., in 2016, found that American’s views on legalizing cannabis indicated that 60% of the population surveyed, believed the substance should be legalized. A recent poll conducted by Quinnipiac University also concluded that 54% of Americans favored the legalization of cannabis without additional constraints, while 81% of respondents favored legalization of cannabis for medicinal purposes. Cannabis was approved for medicinal use in 28 states of the US, the District of Columbia, Guam, and Puerto Rico as of January 2017. Online availability of cannabis-based products is also boosting the market growth as cannabis consumers prefer to buy online from licensed producers or manufacturers.
Key Findings of the Study
  • The global CBD market is projected to reach over USD 22,07,162.54 Million by 2026 at a 58% CAGR during the review period of 2019 to 2026.
  • The Americas accounted for the largest market share with Latin America being the major contributor to the growth of the market.
  • The capsules segment by route of administration is projected to register the highest CAGR of 128.37% during the forecast period. CBD can also be taken in capsule form that allows taking CBD oil without experiencing the taste of CBD. In capsule form, the CBD looks like a soft gel, which is convenient to use with a specific quantity.
Access More Details of the Report @ https://www.marketresearchfuture.com/reports/cbd-market-8090 
Posted by at No comments:
Labels:

Mixed Reality In Healthcare Market Rise With Magnifying Growth Rate | Forecast By 2024

Market Scenario
The global mixed reality in healthcare market is projected to show significant growth over the forecast period. It is estimated that the global mixed reality in healthcare market is expected to register a CAGR 26.3% during the forecast period of 2019 to 2024, with an estimated market value of USD 2,475 million in 2024.
Mixed Reality (MR) is an amalgamation of Augmented Reality (AR) and Virtual Reality (VR), defining the polar ends of a spectrum known as virtuality spectrum or mixed reality spectrum. Augmented reality delivers digital components, whereas virtual reality enables immersive imitation of real-life settings. MR has widespread applications in different fields of healthcare, varying from treatment to training and education. The global mixed reality in healthcare market is fueled by factors such as rapid improvements in the adoption of sensor technology, increase in the user acceptance, increased applications of MR in disease care and treatment, and increasing workload of healthcare professionals. Additionally, the benefits of MR systems such as operational efficiency, increased service quality, and reduced human effort is also projected to drive the growth of the mixed reality in healthcare market. For instance, in 2018, Samsung completed a randomized control trial that showed that VR therapy reduces pain by 52%.
On the other hand, the lack of adequate skill among medical practitioners, high investment costs, occurrences of technical glitches and the concern related to loss of data is likely to curb the growth of the market during the assessment period. Nevertheless, changes in regulatory policies are expected to reduce the impact of barriers over the forecast period.
Moreover, major companies in the market are involved in strategic acquisitions and collaborations to brace their position in the market. For instance, in March 2018, Samsung announced a partnership with Travelers Insurance, Cedars-Sinai Medical Center, Bayer, and AppliedVR to study a virtual reality for pain management.
Segmentation
The global mixed reality in healthcare market has been segmented into component, device type, application, and end user.
The market, based on component, has been segmented into software, hardware, and service. The software segment is expected to hold a major share due to the increased accessibility of software to the users, whereas the hardware segment is projected to be the fastest growing segment owing to ease of availability of hardware components.
The market, by device type, has been segmented into augmented reality in healthcare and virtual reality in healthcare. The AR in healthcare segment is expected to hold a major share due to the increased application of AR for the attenuation of pain perception, whereas VR in healthcare segment is anticipated to be the fastest growing segment owing to rise in awareness and increased research in this field. The market, by augmented reality in healthcare, has been further segmented into head-mounted display (HMD), and handheld device. The market, by virtual reality in healthcare, has been segmented into head-mounted display (HMD), gesture tracking devices, projectors, and others.
The market, by application, has been segmented into surgery simulation, surgery, patient care management, pharmacy care management, fitness management, and others. The surgery simulation segment is expected to hold a major share owing to the increasing use of MR tools for training surgeons due to the anatomically realistic recreations. The segment of surgery is expected to be the fastest growing segment due to the increased patient population in recent years.
The market, by end user, has been segmented into hospital and surgical centers, research organizations, and others. The segment of hospital and surgical centers is projected to hold a major share due to the rise in the hospitals switching to MR systems, whereas the segment of research organizations is expected to be the fastest growing segment due to the increased research initiatives.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The mixed reality in healthcare market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European mixed reality in healthcare market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The mixed reality in healthcare market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The mixed reality in healthcare market in the Middle East & Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

Sunday, 5 April 2020

Global COUGH SYRUP Market Solid Segment Analyzed By Latest Trends, Growth Rate And 2024 Insight

Market Highlights
The Global Cough Syrup Market is estimated to be valued at USD 5,139.63 Million by 2026 and is projected to register a CAGR of 3.45% during the forecast period.
Cough syrups are a medication used for the temporary relief of coughs, sneezing, or runny noses due to the common cold, hay fever, or other upper respiratory allergies.
The increasing incidence of respiratory disorders along with the rising air pollution are some of the key trends contributing to the growth of the cough syrup market. Additionally, the growing geriatric population, along with the strong pharmaceutical sector, is boosting market growth as aged people are more prone to respiratory disorders. Furthermore, the market is expected to witness lucrative growth due to increasing product developments.
However, product recalls, and the stringent regulatory scenario are hampering the growth of the market.
Segment Analysis
The global cough syrup market has been segmented into product type, category, and application. Based on product type, the market has been segregated into combination and individuals. Combination product type has been further sub-segmented into dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine. Based on the category, it has been classified as cough suppressants and expectorants. Based on application, the cough syrup market has been categorized as adults and children.
Market Players
Market Research Future (MRFR) recognizes Pfizer, Inc. (US), Novartis AG (Switzerland), Merck KGaA (US), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline PLC (UK), Acella Pharmaceuticals, LLC (US), Procter & Gamble (US), Reckitt Benckiser Group PLC (UK), Abbott (US), and Sanofi (France) as the key players in the global cough syrup market.
Regional Analysis
The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold a maximum share of the global cough syrup market, and the regional market is projected to register a CAGR of 3.16% during the forecast period. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region.
Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as Novartis, GlaxoSmithKline, and Reckitt Benckiser Group PLC. The cough syrup market in Europe is expected to be driven by the growth of the pharmaceutical industry in Germany, France, and the UK.
Asia-Pacific is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory diseases due to tobacco smoke, exposure to air pollutants at home and the workplace, vehicular pollution, and indoor air pollution from biological agents related to damp and mold further increase the risk of respiratory disease in children and adults in these countries.
The Middle East & Africa cough syrup market has been segmented into major two regions, the Middle East and Africa. The developed countries in the region, such as the UAE and Saudi Arabia, are the ones with the maximum share of the cough syrup market. The advancing healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable income of the people in these countries are some reasons leading to the large share of the market in these countries. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.
Key Findings of the Study:
  • The global cough syrup market was valued at USD 3,920.87 million in 2018, is estimated to grow at USD 5,139.63 million by 2026 at a CAGR of 3.45% during the assessment period.
  • The Americas is expected to hold a maximum share of the global cough syrup market. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region.
  • Based on the category, the cough suppressants segment accounted for the largest market share of 61% in 2018.
  • Based on application, the children segment dominated the market and projected to register the highest CAGR of 78% during the forecast period.
NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Posted by at No comments:
Labels:

GENETIC TESTING Market Size, Share Analysis, Strategies, Revenue And Forecasts To 2024

Market research future will be publishing a cooked research report on “Global Genetic Testing Market” that contains the information from 2019 to 2024. The genetic testing market is expected to grow at a CAGR 11.50% during the forecast period of 2019 to 2024.
Market Research Future (MRFR) recognizes the following companies as the key players in the global genetic testing market that includes Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V.  (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (China), and Thermo Fisher Scientific Inc. (US).
Market Highlights
The genetic testing market is estimated to be valued at USD 22834.19 million by 2024 and expected to grow at a CAGR of 11.50% during the forecast period. Genetic testing also known as DNA testing is a branch of science that can provide information about a person's genes and chromosomes.
Genetic tests can confirm or rule out a suspected genetic condition, and it can help determine a person’s probability of developing a genetic disorder or passing the same to the next generation. Currently, there are more than 1,000 genetic tests in use, and more are being developed.
Segment analysis
The global genetic testing market has been segmented on the basis of type, method, and application. On the basis of type, the market has been divided into prescribed genetic testing and direct to consumer genetic testing. The prescribed genetic testing is holding the major share of the overall genetic testing market. It has been estimated that the prescribed genetic testing is expected to grow at the highest CAGR to reach USD 21653.91 million by the end of 2024.  
Based on method, the genetic testing market is segmented into molecular genetic tests/ DNA tests, chromosomal genetic tests, and biochemical genetic tests. The molecular genetic test/DNA tests account for major share with 11.78% CAGR during the forecast period.
The genetic testing market, by application, is segmented into reproductive health, cancer screening, ancestry, predictive and pre-symptomatic testing, and others. The reproductive health segment accounted for the largest market share of 33.61% in 2018.
Regional Analysis
Geographically, the global genetic testing market is segmented into North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. As per MRFR analysis, the Americas accounted for the largest market share as of 2018 and is projected to grow at the highest CAGR during the forecast period. Increasing genetic diseases and abnormalities, the presence of sophisticated infrastructure, and governmental support for research and development in genetics are the major driving factors for market growth in this region. Europe accounted for the second largest market share owing to technological advances, well-developed health care sector, and governmental support for the research and development of different tests and devices. Asia-Pacific is the fastest growing market for genetic testing owing to the presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market. The Middle East & Africa accounted for the 8.8% market share in 2018.
Key Findings of the Study:
  • Global genetic testing market is projected to reach 22834.19 million by 2024 with 11.50% CAGR during the review period of 2019 to 2024.
  • The Americas accounted for the largest share due to the increasing genetic diseases and abnormalities, the presence of sophisticated infrastructure, and governmental support for research and development in genetics in the region.
  • The molecular genetic test/DNA test segment is the dominant method for the genetic testing market across all regional segments during the forecast period.
  • Prescribed genetic testing is the leading segment, which is growing at the highest CAGR to reach USD 21653.91 million by the end of 2024.
  • Some of the players operating in the genetic testing market are Illumina Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), among others.
NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Posted by at No comments:
Subscribe to: Posts (Atom)